Corcept Therapeutics Inc.

Pharmaceutical Preparations

CORTStrong8 of 10 basics passed

$121.19

+2.24%

Market cap $13.1B

$121.19

+2.24%

Market cap $13.1B

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone.

It is a $13.1B healthcare company. Revenue grew 16.0% over the last year, it keeps 7¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 237.4× earnings — near the highest of its own history.

Website: corcept.com
Location: Redwood City, CA
Employees: 730
Sector: Healthcare

Share price · 3 years

$27.39 → $121.19+342.5%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $831M
Profit: keeps 7¢ of every $1 sold; $55.2M
Free cash flow: cash left after running the business; $107M
Net cash: more cash than debt; $366M
P/E: years of profit in the price; 237.4
EPS: earnings per share, TTM; $0.46
Shares: up 3% since 2016 — dilution; 120.0M
Volatility: beta vs the market — under 1 swings less; 0.52

Revenue, last 10 years

52-week range

Low $32.15$121.19High $123.57

Today's price is 97% of the way from the year's low to its high.

P/E vs its history5y

238.6×median 31.0×

Higher than 100% of past days — near the highest of its own history.

Valuation vs own history

P/E

238.6×

P/S

15.8×

EV/EBITDA

1998.7×

P/B

18.6×

FCF yield

0.8%

Share of the last ~5 years that was pricier than today (unusually expensive vs its own history). Based on the daily valuation record.

Insider activity · 90 days

-$4.89Mnet selling

Purchases$0

Sales$4.89M

Insiders trading, last 14d0 buy · 3 sell

Standing in Healthcare

Size$13.1Btop 68%
Revenue growth+24%top 15%
Net margin7%top 57%
Return on equity8%top 62%
P/E237.4×top 99%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong health, quality and moat; Valuation lags behind.

Valuation10

P/E vs own history100th pct · 0/25
FCF yield0.8% · 5/25
P/S15.8x · 5/25
EV/EBITDA1538.3x · 0/25

Growth50

Revenue CAGR20.1% · 25/25
Net income CAGR-3.0% · 0/25
EPS CAGR ~5Y-0.5% · 0/25
Fwd implied growth612.4% · 25/25

Profitability55

ROIC35.4% · 25/25
ROE8.4% · 12/25
Net margin6.6% · 13/25
Operating margin0.8% · 5/25

Health100

Altman Z44.76 · 25/25
Current ratio2.86 · 25/25
Interest coverage106.6x · 25/25
Net cash / debtNet cash · 25/25

Quality77

Piotroski F5/9 · 15/25
Beneish M-2.69 · 25/25
FCF conversion195% · 25/25
Margin stabilityσ 14.1% · 12/25

Moat100

ROIC >12% years9/9 yrs · 25/25
Median gross margin98.3% · 25/25
FCF-positive years10/10 yrs · 25/25
Worst-year net marginworst 10.0% · 25/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

FY2024Financial
Best year on record
$141M net income
FY2016Financial
Profitable every year on record
10 consecutive profitable years in our data
FY2016Financial
Positive free cash flow every year since
10-year streak

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$59 146 today — price return only

$761.4M revenue in FY2025

Revenue up 16.0% year over year

Profitable 10 years in a row

Positive free cash flow 10 years in a row

730 employees

ROIC of 35.4%

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (98.3%)
Revenue growing 16.0% year over year
Net cash position after subtracting debt from cash
Interest covered 106.6× by operating earnings
High returns on invested capital (ROIC 35.4%)

Watch-outs

Nothing stands out as a concern in the available data.

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

8 of 10 checks passed

Revenue growing — the company sells more than a year ago+16.0% YoY
Profitable — makes more than it spends$55.2M TTM
Profit growing — earnings are higher than last year-1.7% YoY
Generates cash — cash left after running and investing$107M TTM
Debt under control — could handle its obligationsmore cash than debt
Established company — not a micro-cap — lower blow-up risk$13.1B market cap
Not printing shares — share count not ballooning — you keep your slice-3.4% shares over ~5y
Proven track record — years of profitability behind it10/10 profitable years
Financially stable — balance sheet not near distressAltman Z 44.8 — safe
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsP/E 237.4

Peer comparisonCorcept Therapeutics Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
CORT this company	$13.1B	237.4	+16.0%	6.6%	Strong
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: CORT vs LLY · CORT vs JNJ · CORT vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 3Buy 7Hold 1Strong sell 1

Appendix · Financial records

The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $831M · net income $55.2M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$831M

YoY 16.0%

Net income (TTM)

$55.2M

Margin 6.6%

Gross margin

98.3%

Operating margin

0.8%

P/E ratio

237.4

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	0.4	0.4	0.4	0.5	0.7	0.8
Gross profit	0.3	0.4	0.4	0.5	0.7	0.7
Operating income (EBIT)	0.1	0.1	0.1	0.1	0.1	0.0
Net income	0.1	0.1	0.1	0.1	0.1	0.1
EPS (diluted)	0.85	0.89	0.87	0.95	1.24	0.83

Cash flowFree cash flow $107M · operating cash flow $110M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

$107M

Margin 12.9%

Operating cash flow (TTM)

$110M

FCF margin

12.9%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	0.2	0.2	0.1	0.1	0.2	0.1
Capital expenditure	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0
Free cash flow	0.2	0.2	0.1	0.1	0.2	0.1
FCF margin	42.6%	45.7%	29.8%	26.3%	29.0%	18.6%

Balance sheetAssets $837M · net cash $366M (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $837M of assets is financed

23%

77%

Liabilities $189M — borrowed moneyEquity $648M — owners' stake

Cash vs debt

Total debt $6.11M − cash $372M = net cash $366M

Cash on hand covers all debt.

Altman Z-Score

44.76

Safe zone

Debt repayment

Not needed

Cash already covers all debt

Interest coverage

106.6x

EBIT ÷ interest expense

ROE

8.4%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.4	0.2	0.4	0.4	0.4	0.4
Total assets	0.6	0.4	0.6	0.6	0.8	0.8
Total liabilities	0.0	0.0	0.1	0.1	0.2	0.2
Total debt	—	0.0	0.0	0.0	0.0	0.0
Equity	0.5	0.4	0.5	0.5	0.7	0.6
Net debt	—	-0.2	-0.4	-0.4	-0.4	-0.4

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of CORT on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $121.19 · market cap $13.1B.